Newsletter | November 17, 2026

11.17.26 -- How To Build A Medicine When Someone Is Waiting For A Dose

INDUSTRY INSIGHTS

Solving The DNA Knock-In Problem

An in‑depth exploration of why large, precise DNA knock‑ins limit cell therapy progress—and how site‑specific integration enables durable, scalable genetic engineering solutions.

Quality Agreements, Tech Transfer & Risk Management In CGT

Early quality, strong tech transfer, solid data discipline, and risk‑based decisions help accelerate advanced therapy programs and ensure compliance, scalability, and regulatory confidence.

Developing Scalable, Global Solutions For Cell & Gene Manufacturing

Cell and gene therapies offer transformative potential for treating complex diseases, but their manufacturing and global delivery face significant challenges.

FEATURED EDITORIAL

How To Build A Medicine When Someone Is Waiting For A Dose

Over two days in Boston, biopharma leaders at CDMO Live Americas confronted a blunt truth: the outsourcing sector doesn't lack ambition or stainless steel, it has a widening gap between partnership intent and shop-floor delivery.

AI, Investigation, And The Mystery Of The Missing Half-Pill

A number of patients report receiving half a pill in a blister pack of their prescribed medicine. The initial sponsor reaction is to place the problem at an external partner’s production or packaging line. But overall responsibility lies with the sponsor, and the true extent of the problem is hard to detect. Enter AI. Experienced pharma quality expert Damiano Dragone believes AI combined with professionals throughout the supply chain can join in a new “logic and creativity" to improve our industry on behalf of patients.

Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review

Determining whether a drug manufacturing environment is stable, drifting, or developing a recurring loss-of-control signal requires integrated trend evaluation.

INDUSTRY INSIGHTS CONTINUED

Overcoming Lentiviral Vector Challenges

Lentiviral vector fragility and the lack of tools to separate full from empty particles complicate downstream processing, while analytics and manufacturing expertise change how developers respond.

Personalized Cancer Vaccines: The Science Is Ready. Is The Manufacturing?

Late-stage melanoma data and long-term survival signals in the hardest solid tumors point to a viable personalized neoantigen vaccine strategy, but a fixed biological timeline strains upstream production.

Simplifying Adenoviral Purification For Scalable Manufacturing

As vector design advances, downstream purification limits adenoviral manufacturing. A membrane-integrated hybrid train reduces product loss and process complexity at scale.

What FDA CRLs Reveal About Cell-Based Potency Assays

Cell-based potency assays are critical for defining drug quality, yet frequent FDA CRLs cite assay deficiencies. Learn key pitfalls and strategies to strengthen validation and regulatory readiness.

Vial Containment Systems For Gene Therapies

Research across AAV, adenovirus, and lentivirus vectors shows cyclic olefin polymer vial systems match or outperform borosilicate glass on viral vector recovery and container closure integrity.

Enabling Effective Passive And Active Immune Cell Targeting Strategies

Targeted LNPs that bypass the liver and home to the spleen could reshape in vivo CAR T cell manufacturing. See the data behind the approach.

Using Synthetic ssDNA And dsDNA Templates For CRISPR Editing

Synthetic ssDNA and dsDNA donor templates boost CRISPR precision, efficiency, and consistency. The right strategy reduces errors, increases HDR, and delivers more reliable results across applications.

Balancing Early-Stage Needs With Future Success

Streamlining the tech transfer process is a key variable in shortening development timelines and controlling costs, maximizing a molecule's potential for late-stage success.

Using Rapid Development To Accelerate CGT Development

Assimilate how the following framework can accelerate your viral vector, CAR-T, and iPSC programs, reduce risk, and streamline your path from development to commercial manufacturing.

SOLUTIONS

A Flexible Platform For Growing mRNA Pipelines

Inside The Technology Advancing CHO Therapeutic Protein Expression

Pox Virus, VSV And HSV Platforms

Point‑Of‑Care CAR‑T Manufacturing

Rapid Antibody Gene-To-Drug Substance

OUTSOURCED PHARMA CAPABILITIES UPDATE

Find Your New CDMO At Outsourced Pharma Capabilities Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: